Identification of combinatorial drug therapy against triple negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC) using a functional profiling approach.

Main aim is to functionally classify triple negative breast cancer and pancreatic adenocarcinoma cell lines, directly connecting to druggable vulnerabilities and identify their putative biomarkers. After establishing selective signaling node vulnerabilities, I will further investigate to identify and validate selective drug combinations against both tumor types that could be translated to the clinics.